Drug intelligence / Profile preview

JNJ-54416076

Development stage: Phase 1
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

JNJ-54416076 is an investigational small molecule drug that was developed by Johnson & Johnson, specifically through its subsidiary Janssen Research & Development. The compound advanced to Phase 1 clinical trials, where it was evaluated for safety, tolerability, pharmacokinetics, and the effect of food on its absorption in healthy male subjects. The precise mechanism of action for JNJ-54416076 remains unknown and has not been publicly disclosed. As of the latest available information, development of this drug has been discontinued and it is no longer in active clinical development[1][2][4].

Beyond the preview

Go deeper on JNJ-54416076.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-54416076.

Explore the full profile